皇家制药版税

最新新闻

• 评级变动
  TD Cowen Maintains Royalty Pharma(RPRX.US) With Buy Rating, Raises Target Price to $65
  \u5e02\u573a\u8d44\u8baf · 2026/7/13
• 评级变动
  UBS Maintains Royalty Pharma(RPRX.US) With Buy Rating, Raises Target Price to $66
  \u5e02\u573a\u8d44\u8baf · 2026/8/11
• 评级变动
  TD Cowen Maintains Royalty Pharma(RPRX.US) With Buy Rating, Raises Target Price to $68
  \u5e02\u573a\u8d44\u8baf · 2026/9/8
• 评级变动
  Morgan Stanley Maintains Royalty Pharma(RPRX.US) With Buy Rating, Raises Target Price to $64
  \u5e02\u573a\u8d44\u8baf · 2026/5/7
• 评级变动
  J.P. Morgan Maintains Royalty Pharma(RPRX.US) With Buy Rating, Raises Target Price to $62
  \u5e02\u573a\u8d44\u8baf · 2026/8/11
• 评级变动
  BofA Securities Maintains Royalty Pharma(RPRX.US) With Buy Rating
  \u5e02\u573a\u8d44\u8baf · 2026/7/10
• Morgan Stanley Maintains Royalty Pharma(RPRX.US) With Buy Rating, Raises Target Price to $67
  \u5e02\u573a\u8d44\u8baf · 2026/10/7
• BofA Securities Maintains Royalty Pharma(RPRX.US) With Buy Rating, Maintains Target Price $63
  \u5e02\u573a\u8d44\u8baf · 2026/10/9
• UBS Maintains Royalty Pharma(RPRX.US) With Buy Rating, Maintains Target Price $66
  \u5e02\u573a\u8d44\u8baf · 2026/9/8
• 评级变动
  Morgan Stanley Maintains Royalty Pharma(RPRX.US) With Buy Rating, Raises Target Price to $65
  \u5e02\u573a\u8d44\u8baf · 2026/8/6
• 评级变动
  Citi Maintains Royalty Pharma(RPRX.US) With Buy Rating, Maintains Target Price $70
  \u5e02\u573a\u8d44\u8baf · 2026/9/9
• BofA Securities Maintains Royalty Pharma(RPRX.US) With Buy Rating, Announces Target Price $63
  \u5e02\u573a\u8d44\u8baf · 2026/9/24
• Royalty Pharma(RPRX.US) Officer Sells US$5.85 Million in Common Stock
  \u5e02\u573a\u8d44\u8baf · 2026/9/25
• 评级变动
  Goldman Sachs Maintains Royalty Pharma(RPRX.US) With Buy Rating, Raises Target Price to $66
  \u5e02\u573a\u8d44\u8baf · 2026/8/7
• 评级变动
  Citi Maintains Royalty Pharma(RPRX.US) With Buy Rating, Maintains Target Price $66
  \u5e02\u573a\u8d44\u8baf · 2026/7/16
• 评级变动
  J.P. Morgan Maintains Royalty Pharma(RPRX.US) With Buy Rating, Raises Target Price to $58
  \u5e02\u573a\u8d44\u8baf · 2026/5/7
• 评级变动
  BofA Securities Maintains Royalty Pharma(RPRX.US) With Buy Rating, Raises Target Price to $62
  \u5e02\u573a\u8d44\u8baf · 2026/5/7
• 评级变动
  Morgan Stanley Maintains Royalty Pharma(RPRX.US) With Buy Rating, Maintains Target Price $65
  \u5e02\u573a\u8d44\u8baf · 2026/8/7
• 评级变动
  Goldman Sachs Maintains Royalty Pharma(RPRX.US) With Buy Rating, Raises Target Price to $59
  \u5e02\u573a\u8d44\u8baf · 2026/5/7
• 评级变动
  Citi Maintains Royalty Pharma(RPRX.US) With Buy Rating, Raises Target Price to $70
  \u5e02\u573a\u8d44\u8baf · 2026/8/6
• 评级变动
  UBS Maintains Royalty Pharma(RPRX.US) With Buy Rating, Raises Target Price to $57
  \u5e02\u573a\u8d44\u8baf · 2026/4/21
• Form 144 | Royalty Pharma(RPRX.US) Officer Proposes to Sell 5.85 Million in Common Stocks
  \u5e02\u573a\u8d44\u8baf · 2026/9/23

新闻标题为自动聚合内容，未经我们团队独立核实或编辑。